3 minutes checked out
Oct. 5, 2023– People taking popular medications like Ozempic, Wegovy, and Rybelsus for weight reduction are at greater danger for possibly major stomach and digestive tract concerns, compared to individuals taking a weight reduction drug authorized in 2014, a big research study exposes.
Those taking among these drugs, referred to as glucagon-like peptide-1 (GLP-1) receptor agonists, were 9 times most likely to have pancreatitis, a frequently uncomfortable swelling of the pancreas, compared to others taking a mix of naltrexone and bupropion for weight reduction (brand Contrave).
Other findings reveal that individuals taking these drugs:
- Were over 4 times most likely to get a bowel blockage, which avoids food from going through the big or little intestinal tracts, with signs like queasiness, throwing up, constraining and/or bloating
- Were more than three-and-a-half times most likely to get stomach paresis, an obstruction of food in the stomach that can trigger queasiness, throwing up, and stomach discomfort
The research study was released today in the Journal of the American Medical Association
Scientists state their findings are not about frightening individuals off the weight reduction drugs, however rather about increasing awareness that these prospective negative results can take place. That method, individuals can think about the threats and advantages prior to beginning these medications.
Unusual But There
Individuals taking these drugs for weight reduction have about a 1% to 2% opportunity of having these occasions, consisting of a 1% danger for stomach paresis, stated Mahyar Etminan, PharmD, the research study’s senior author and a specialist in drug security and pharmacoepidemiology at the University of British Col